Department of Medicine/Dermatology, University of Washington, Seattle, Washington 98109, USA.
J Invest Dermatol. 2013 Aug;133(8):2065-73. doi: 10.1038/jid.2013.36. Epub 2013 Jan 25.
Merkel cell carcinoma (MCC) is an aggressive, polyomavirus-linked skin cancer. Although CD8 lymphocyte infiltration into the tumor is strongly correlated with improved survival, these cells are absent or sparse in most MCCs. We investigated whether specific mechanisms of T-cell migration may be commonly disrupted in MCC tumors with poor CD8 lymphocyte infiltration. Intratumoral vascular E-selectin, critical for T-cell entry into skin, was downregulated in the majority (52%) of MCCs (n=56), and its loss was associated with poor intratumoral CD8 lymphocyte infiltration (P<0.05; n=45). Importantly, survival was improved in MCC patients whose tumors had higher vascular E-selectin expression (P<0.05). Local nitric oxide (NO) production is one mechanism of E-selectin downregulation and it can be tracked by quantifying nitrotyrosine, a stable biomarker of NO-induced reactive nitrogen species (RNS). Indeed, increasing levels of nitrotyrosine within MCC tumors were associated with low E-selectin expression (P<0.05; n=45) and decreased CD8 lymphocyte infiltration (P<0.05, n=45). These data suggest that one mechanism of immune evasion in MCC may be restriction of T-cell entry into the tumor. Existing therapeutic agents that modulate E-selectin expression and/or RNS generation may restore T-cell entry and could potentially synergize with other immune-stimulating therapies.
默克尔细胞癌(Merkel cell carcinoma,MCC)是一种侵袭性的、与多瘤病毒相关的皮肤癌。虽然 CD8 淋巴细胞浸润肿瘤与改善生存强烈相关,但在大多数 MCC 中,这些细胞缺失或稀疏。我们研究了在 CD8 淋巴细胞浸润不良的 MCC 肿瘤中,T 细胞迁移的特定机制是否可能普遍受到破坏。肿瘤内血管 E-选择素对于 T 细胞进入皮肤至关重要,在大多数(52%)MCC 中(n=56)下调,其缺失与肿瘤内 CD8 淋巴细胞浸润不良相关(P<0.05;n=45)。重要的是,血管 E-选择素表达较高的 MCC 患者的生存得到改善(P<0.05)。局部一氧化氮(NO)产生是 E-选择素下调的一种机制,可以通过定量硝基酪氨酸来跟踪,硝基酪氨酸是 NO 诱导的活性氮物种(RNS)的稳定生物标志物。事实上,MCC 肿瘤内硝基酪氨酸水平的升高与 E-选择素表达降低(P<0.05;n=45)和 CD8 淋巴细胞浸润减少相关(P<0.05,n=45)。这些数据表明,MCC 中免疫逃避的一种机制可能是限制 T 细胞进入肿瘤。现有的调节 E-选择素表达和/或 RNS 生成的治疗药物可能恢复 T 细胞进入,并可能与其他免疫刺激疗法协同作用。